ScholarIQanswers from OpenAlex
Guangxi Zhuang Autonomous Region Health and Family Planning
InstitutionResearch output, impact & collaborations
Guangxi Zhuang Autonomous Region Health and Family Planning is a institution indexed in ScholarIQ from OpenAlex.
What is known about Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQrecord summary
Guangxi Zhuang Autonomous Region Health and Family Planning is a research organisation in Nanning, CN. OpenAlex records 1,524 works and 17,435 citations for it. 996 researchers list it as their most recent affiliation.
How many works does Guangxi Zhuang Autonomous Region Health and Family Planning have?
ScholarIQindexed works
Guangxi Zhuang Autonomous Region Health and Family Planning has 1,524 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Guangxi Zhuang Autonomous Region Health and Family Planning have?
ScholarIQcitation count
Guangxi Zhuang Autonomous Region Health and Family Planning has 17,435 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQresearcher count
Guangxi Zhuang Autonomous Region Health and Family Planning has 996 researchers in the ScholarIQ index.
What is the average h-index at Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQavg h-index
Guangxi Zhuang Autonomous Region Health and Family Planning has an average h-index of 64 in OpenAlex.
What is the ROR of Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQror
The ROR for Guangxi Zhuang Autonomous Region Health and Family Planning is on the source record.
What is the OpenAlex record for Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQopenalex
The OpenAlex for Guangxi Zhuang Autonomous Region Health and Family Planning is on the source record.
Who are the most-cited researchers behind Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQtop researchers by citations
What are the most-cited papers on Guangxi Zhuang Autonomous Region Health and Family Planning?
ScholarIQmost cited works
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok, Yi‐Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, H.Z. Turna, Gilberto de Castro, Vichien Srimuninnimit, К. К. Лактионов, Igor Bondarenko, Kaoru Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, Grigory Adamchuk, Myung‐Ju Ahn, Aurelia Alexandru, Özden Altundağ, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, António Araújo, Osvaldo Rudy Aren, Oscar Arrieta Rodriguez, Touch Ativitavas, Oscar Avendaño, Fernando Barata, Carlos H. Barrios, Carlos Beato, Per Bergström, Daniel Betticher, Л. В. Болотина, Igor Bondarenko, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andrés F. Cardona, Gilberto de Castro, Hugo R. Castro, Filiz Çay Şenler, Carlos Alexandre Sydow Cerny, Alvydas Česas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao‐Hua Chiu, Byoung Chul Cho, Saulius Cicėnas, Daniel Ciurescu, Graham Cohen, Marcos André Costa, Pongwut Danchaivijitr, Flávia De Angelis, Sérgio Jobim Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, S. A. Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo dos Santos Fernandes, Carlos Gil Ferreira, Fábio Franke, H. Freitas, Yasuhito Fujisaka, Héctor Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Göker, Tuncay Göksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Håkan Griph, Mahmut Gümüş, Jacqueline A. Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernández Hernández, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi, Jianming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jinwan Wang, Hiroto Miwa, Shukui Qin, Ik‐Joo Chung, Kun‐Huei Yeh, Jifeng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung‐Jue Bang
How much of the research on Guangxi Zhuang Autonomous Region Health and Family Planning is open access?
ScholarIQopen access share
50%OPEN ACCESS